Synthesis of two potential anticancer copper(ii) complex drugs: their crystal structure, human serum albumin/DNA binding and anticancer mechanism
New Journal of Chemistry, ISSN: 1369-9261, Vol: 41, Issue: 5, Page: 2062-2072
2017
- 39Citations
- 25Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Two hydrazone ligands 8-quinolinecarbaldehyde 3-methoxybenzoylhydrazone (L1) and 8-quinolinecarbaldehyde benzoylhydrazone (L2) and the corresponding mononuclear copper(ii) complexes [Cu(L1)(NO)] (1) and [Cu(L2)(CHO)NO] (2) have been synthesized. The structures of complexes 1 and 2 were characterized by X-ray crystallography, elemental analyses, FT-IR and HRMS (ESI). Efficient binding of the complexes (1 and 2) and ligands (L1 and L2) with protein (human serum albumin, HSA) has been established by UV-vis, fluorescence, synchronous fluorescence spectroscopy, and molecular docking methods. Fluorescence spectra show that both complexes strongly interact with protein. And the Trp residue, the intrinsic fluorophore in HSA, was induced to a less hydrophobic microenvironment with the addition of test complexes. Meanwhile, the fluorescence quenching mechanism was determined to be static quenching. Interaction of the complexes (1 and 2) and ligands (L1 and L2) with calf-thymus DNA (CT-DNA) has been investigated by UV-vis and fluorescence methods which showed that the compounds interacted with CT-DNA through intercalation. Moreover, the molecular docking study indicated that the complex is embedded into site I (subdomain IIA) of HSA. In addition, the complexes exhibited significant cytotoxicity against a human cervical cancer cell line (HeLa), and complexes 1 and 2 showed better activity than cisplatin. The complexes could cause HeLa cell cycle arrest at the G2 phase. And mitochondrial dysfunction was induced by both of the complexes.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85014416840&origin=inward; http://dx.doi.org/10.1039/c6nj02483a; https://xlink.rsc.org/?DOI=C6NJ02483A; http://xlink.rsc.org/?DOI=C6NJ02483A; http://pubs.rsc.org/en/content/articlepdf/2017/NJ/C6NJ02483A; https://dx.doi.org/10.1039/c6nj02483a; https://pubs.rsc.org/en/content/articlelanding/2017/nj/c6nj02483a
Royal Society of Chemistry (RSC)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know